| Market Cap | 1.85M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.77M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 219.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -63.00% |
| Recommedations | - | Quick Ratio | 0.45 | Shares Outstanding | 495.09K | 52W Low Chg | 7,560.00% |
| Insider Own | 1.19% | ROA | -98.67% | Shares Float | 489.21K | Beta | 1.51 |
| Inst Own | - | ROE | -653.73% | Shares Shorted/Prior | 2.52K/4.23K | Price | 3.83 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 78,193 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 12 | Volume | 3,435 | Change | 66.52% |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent which targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.